Dr. David Vocadlo completed his PhD at the University of British Columbia in 2002. He was a postdoctoral fellow at the University of California at Berkeley in the Departments of Chemistry and Molecular and Cell Biology (2002–2003). In 2004, he moved to Simon Fraser University (SFU), where he is now professor in the Departments of Chemistry and Molecular Biology & Biochemistry and Tier I Canada Research Chair in Chemical Biology. His research focuses on developing chemical biology tools to advance understanding the roles of glycoconjugates in health and disease. Dr. Vocadlo pioneered the creation and preclinical validation of OGA inhibitors for neurodegenerative diseases, a strategy now advanced into clinic trials. His research has been recognized with various awards including the EWR Steacie Memorial Fellowship, the Horace Isbell Award of the American Chemical Society, and appointment as an inaugural member of the Royal Society of Canada, College of New Scholars.